PDF) WTX101 in patients newly diagnosed with Wilson disease: final

PDF) Wilson's Disease: Clinical Practice Guidelines of the Indian National Association for Study of the Liver, the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition, and the Movement Disorders Society of India

PDF) Ammonium tetrathiomolybdate in the decoppering phase treatment of Wilson's disease with neurological symptoms: A case series

Full article: Metabolic disposition of WTX101 (bis-choline tetrathiomolybdate) in a rat model of Wilson disease

Table of Contents page: Journal of Hepatology

PDF) WTX101 in patients newly diagnosed with Wilson disease: final results of a global, prospective phase 2 trial

Full article: Metabolic disposition of WTX101 (bis-choline tetrathiomolybdate) in a rat model of Wilson disease

Aftab ALA, Professor, MBBS MD PhD FRCP, University of Surrey, Guildford, School of Biosciences and Medicine & Department of Health Management and Strategy

Full article: Metabolic disposition of WTX101 (bis-choline tetrathiomolybdate) in a rat model of Wilson disease

Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent

Full article: A review and update on the diagnosis and treatment of neuropsychiatric Wilson disease

Updates on Wilson disease : Clinical Liver Disease

Full article: Metabolic disposition of WTX101 (bis-choline tetrathiomolybdate) in a rat model of Wilson disease

Bis-choline tetrathiomolybdate prevents copper-induced blood–brain barrier damage

The current Status and New Advances in Diagnosis and Treatment of Wilson Disease – Biomedical and Pharmacology Journal